Literature DB >> 8680752

Intravenous fumonisin B1 induces cell proliferation and apoptosis in the rat.

C W Lim1, H M Parker, R F Vesonder, W M Haschek.   

Abstract

In the rat, the target organs of fumonisin B1, a mycotoxin produced by Fusarium moniliforme, are the kidney and liver. Fumonisin B1 is also hepatocarcinogenic in the rat and is associated epidemiologically with esophageal cancer in humans. We investigated the effect of a single intravenous dose of fumonisin B1 on cell proliferation, lesion development, and glutathione status in the major target organs of the rat. Male Sprague-Dawley rats were injected intravenously with fumonisin B1 at 0 or 1.25 mg/kg and were euthanized at 12 hr or, 1,2,3, or 5 days. An intraperitoneal injection of 5-bromo-2'-deoxyuridine at 100 mg/kg was given 90 min prior to euthanasia. In fumonisin B1 treated rats, serum cholesterol and serum urea nitrogen were elevated; however, the activity of hepatic enzymes was unaffected. Hepatic and renal glutathione concentrations were depressed at 12 and 24 hr, respectively, with subsequent recovery. Histologic changes were most prominent in the outer medulla of the kidney, with cell proliferation and apoptosis followed by nephrosis. Cell proliferation also occurred in the liver and esophagus, but in the absence of tissue injury. The labeling index peaked on day 1 for the liver and on day 3 for the esophagus. These results confirm that the primary target organ of fumonisin B1 in the rat is the kidney and support the concept that fumonisin B1-induced mitogenesis may be the mechanism of carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8680752     DOI: 10.1002/19960401nt5

Source DB:  PubMed          Journal:  Nat Toxins        ISSN: 1056-9014


  8 in total

1.  In vivo effects of fumonisin B1-producing and fumonisin B1-nonproducing Fusarium moniliforme isolates are similar: fumonisins B2 and B3 cause hepato- and nephrotoxicity in rats.

Authors:  K A Voss; R D Plattner; R T Riley; F I Meredith; W P Norred
Journal:  Mycopathologia       Date:  1998       Impact factor: 2.574

2.  Effects of Ginkgo biloba extract on cytoprotective factors in rats with duodenal ulcer.

Authors:  Jane C J Chao; Huei-Chen Hung; Sheng-Hsuan Chen; Chia-Lang Fang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

Review 3.  Polycystic kidney disease: an unrecognized emerging infectious disease?

Authors:  M A Miller-Hjelle; J T Hjelle; M Jones; W R Mayberry; M A Dombrink-Kurtzman; S W Peterson; D M Nowak; F S Darras
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

Review 4.  An overview of rodent toxicities: liver and kidney effects of fumonisins and Fusarium moniliforme.

Authors:  K A Voss; R T Riley; W P Norred; C W Bacon; F I Meredith; P C Howard; R D Plattner; T F Collins; D K Hansen; J K Porter
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

Review 5.  Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis.

Authors:  R T Riley; E Enongene; K A Voss; W P Norred; F I Meredith; R P Sharma; J Spitsbergen; D E Williams; D B Carlson; A H Merrill
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

6.  Fumonisin b1 carcinogenicity in a two-year feeding study using F344 rats and B6C3F1 mice.

Authors:  P C Howard; R M Eppley; M E Stack; A Warbritton; K A Voss; R J Lorentzen; R M Kovach; T J Bucci
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

7.  Dose and Exposure Time-Dependent Renal and Hepatic Effects of Intraperitoneally Administered Fumonisin B₁ in Rats.

Authors:  András Szabó; Judit Szabó-Fodor; Mariam Kachlek; Miklós Mézes; Krisztián Balogh; Róbert Glávits; Omeralfaroug Ali; Yarsmin Yunus Zeebone; Melinda Kovács
Journal:  Toxins (Basel)       Date:  2018-11-09       Impact factor: 4.546

8.  Protective effects of silymarin on fumonisin B₁-induced hepatotoxicity in mice.

Authors:  Mahmut Sozmen; Alparslan Kadir Devrim; Recai Tunca; Murat Bayezit; Serpil Dag; Dinc Essiz
Journal:  J Vet Sci       Date:  2013-10-18       Impact factor: 1.672

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.